MedPath
HSA Approval

Granisetron Kabi concentrate for solution for infusion 1mg/ml

SIN14409P

Granisetron Kabi concentrate for solution for infusion 1mg/ml

Granisetron Kabi concentrate for solution for infusion 1mg/ml

September 23, 2013

FRESENIUS KABI (SINGAPORE) PTE LTD

FRESENIUS KABI (SINGAPORE) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantFRESENIUS KABI (SINGAPORE) PTE LTD
Licence HolderFRESENIUS KABI (SINGAPORE) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INFUSION, SOLUTION CONCENTRATE

INTRAVENOUS

Medical Information

A04A A02

xa 04 a a 02

Manufacturer Information

FRESENIUS KABI (SINGAPORE) PTE LTD

LABESFAL – Laboratórios Almiro S.A. (Fresenius Kabi Group)

Active Ingredients

Granisetron Hydrochloride 1.12mg/ml eqv Granisetron

1mg/ml

Granisetron

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Granisetron Kabi concentrate for solution for infusion 1mg/ml - HSA Approval | MedPath